Online citations, reference lists, and bibliographies.
← Back to Search

Extrapleural Pneumonectomy Versus Pleurectomy/decortication In The Surgical Management Of Malignant Pleural Mesothelioma: Results In 663 Patients.

R. Flores, H. Pass, V. Seshan, Joseph Dycoco, M. Zakowski, M. Carbone, M. Bains, V. Rusch
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVE The optimal procedure for resection of malignant pleural mesothelioma is controversial, partly because previous analyses include small numbers of patients. We performed a multi-institutional study to increase statistical power to detect significant differences in outcome between extrapleural pneumonectomy and pleurectomy/decortication. METHODS Patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy or pleurectomy/decortication at 3 institutions were identified. Survival and prognostic factors were analyzed by the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis. RESULTS From 1990 to 2006, 663 consecutive patients (538 men and 125 women) underwent resection. The median age was 63 years (range, 26-93 years). The operative mortality was 7% for extrapleural pneumonectomy (n = 27/385) and 4% for pleurectomy/decortication (n = 13/278). Significant survival differences were seen for American Joint Committee on Cancer stages 1 to 4 (P < .001), epithelioid versus non-epithelioid histology (P < .001), extrapleural pneumonectomy versus pleurectomy/decortication (P < .001), multimodality therapy versus surgery alone (P < .001), and gender (P < .001). Multivariate analysis demonstrated a hazard rate of 1.4 for extrapleural pneumonectomy (P < .001) controlling for stage, histology, gender, and multimodality therapy. CONCLUSION Patients who underwent pleurectomy/decortication had a better survival than those who underwent extrapleural pneumonectomy; however, the reasons are multifactorial and subject to selection bias. At present, the choice of resection should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned.
This paper references
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
K. Allen (1994)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Surgical treatment of pleural mesothelioma.
P. McCormack (1982)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
V. Gupta (2005)
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
C. Lu (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
AJCC cancer staging handbook
F. L. Greene (2002)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)

This paper is referenced by
Malignant Pleural Mesothelioma -A Clinical Study of 81 Patients from Okayama Rosai Hospital-
H. Nishi (2009)
Multimodality therapy for malignant pleural mesothelioma: surgery plus chemoradiotherapy?
Andrea S. Wolf (2015)
Induction or adjuvant chemotherapy for radical multimodality therapy
Annabel J Sharkey (2018)
Macrophages in Mesothelioma : Improving immunotherapy in pulmonary oncology
Sanne Lievense (2017)
Analysis of survival of patients with metastatic malignant pleural mesothelioma.
Andrea Billè (2020)
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.
M. Ashton (2017)
Deciduoid pleural mesothelioma--a rare entity in a young woman.
C. Santos (2012)
Extra-pleural pneumonectomy.
Leonardo Duranti (2019)
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
Management of Malignant Pleural Effusion
J. Kastelik (2012)
Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy
H. Ishibashi (2015)
Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
M. Kuçukoner (2014)
Regionale Versorgung des malignen Pleuramesothelioms
M. Ried (2013)
Optimizing hemithoracic pleural intensity-modulated radiation therapy for malignant pleural mesothelioma
Fauzia Shaikh (2015)
Clinical Analysis of 27 Patients with Malignant Pleural Mesothelioma Treated at Our Institution
Hajime Kikuchi (2015)
Systemic treatment of malignant pleural mesothelioma.
F. Grosso (2012)
Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?
N. van Zandwijk (2012)
An overview of how asbestos exposure affects the lung
G. Currie (2009)
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma
M. Hashimoto (2019)
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
O. Rena (2015)
Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
M. Hamasaki (2016)
Advances in treatment of mesothelioma
C. Maggioni (2016)
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
G. Gordon (2009)
Association of malignant mesothelioma and asbestos related conditions with ovarian cancer: shared biomarkers and a possible etiological link?
Alex J. Rai (2011)
Prognostic factors in malignant pleural mesothelioma: role of talc pleurodesis
Bassel Al-Alao (2012)
Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
M. You (2014)
ERRATUM for a missing eComment to 'Intrathoracic chemo-thermotherapy with radiofrequency waves after extrapleural pneumonectomy for malignant pleural mesothelioma' (Interact CardioVasc Thorac Surg 2011;13:267-270)
Toshiteru Tokunaga (2011)
Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach.
M. Hoffmann (2010)
Consensus of the AustrianMesothelioma Interest Group (AMIG)
C. Geltner (2016)
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
B. Balduyck (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar